Genes associate with abnormal bone cell activity in bone metastasis (Q38019409)

27 August 2017

Genes associate with abnormal bone cell activity in bone metastasis (English)

1 reference

27 August 2017

G David Roodman

1

1 reference

27 August 2017

1 December 2012

1 reference

Cancer and Metastasis Reviews

27 August 2017

1 reference

27 August 2017

31

1 reference

27 August 2017

3-4

1 reference

27 August 2017

569-578

1 reference

https://scigraph.springernature.com/pub.10.1007/s10555-012-9372-x

27 August 2017

0 references

cites work

Management of bone metastases

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Metastasis to bone: causes, consequences and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Tumor-host cell interactions in the bone disease of myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Mechanisms of bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Osteoclasts are important for bone angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

RANK is essential for osteoclast and lymph node development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Tumour cells produce receptor activator of NF-kappaB ligand (RANKL) in skeletal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Cell biology of the osteoclast

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

RANKing intracellular signaling in osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Regulation of cancer cell migration and bone metastasis by RANKL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Molecular mechanisms of osteolytic bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Parathyroid hormone related protein (PTHrP) in tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Annexin II expressed by osteoblasts and endothelial cells regulates stem cell adhesion, homing, and engraftment following transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Annexins--unique membrane binding proteins with diverse functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Annexin II tetramer: structure and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Cloning and characterization of the annexin II receptor on human marrow stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

A molecular compendium of genes expressed in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Advances in the biology and treatment of bone disease in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Role of decorin in the antimyeloma effects of osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Transcription factors in bone: developmental and pathological aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Osteoblast function in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

The effect of timing in the administration of hepatocyte growth factor to modulate BMP-2-induced osteoblast differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Novel therapies targeting the myeloma cell and its bone marrow microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Tumor necrosis factor inhibits mesenchymal stem cell differentiation into osteoblasts via the ubiquitin E3 ligase Wwp1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

RUNX2 regulates the effects of TNFalpha on proliferation and apoptosis in SaOs-2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Sclerostin is overexpressed by plasma cells from multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFβ-dependent expression of the Wnt antagonist, sclerostin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Sclerostin: a gem from the genome leads to bone-building antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Role of endothelin-1 in osteoblastic bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Effects of selective endothelin ET(A) receptor antagonists on endothelin-1-induced potentiation of cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

Increased expression of macrophage inflammatory protein-1α on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9372-X

10.1007/S10555-012-9372-X

21 January 2018

Identifiers

DOI

1 reference

PubMed ID

22706844

Dimensions Publication ID

27 August 2017

0 references

1 reference

PubMed ID

22706844